Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery

AIM: Pharmacogenetic studies have identified the presence of the HLA-A*31:01 allele as a predictor of cutaneous adverse drugs reactions (ADRs) to carbamazepine. This study aimed to ascertain the preferences of patients and clinicians to inform carbamazepine pharmacogenetic testing services. METHODS:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Powell, Graham, Holmes, Emily A F, Plumpton, Catrin O, Ring, Adele, Baker, Gus A, Jacoby, Ann, Pirmohamed, Munir, Marson, Anthony G, Hughes, Dyfrig A
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2015
Matèries:
Pharmacogenetics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631187/
https://ncbi.nlm.nih.gov/pubmed/26138622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12715
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars